A new class of asthma medications called biologics has become so effective that some patients are experiencing what doctors describe as clinical remission, with symptoms vanishing entirely and rescue inhalers sitting untouched in medicine cabinets. At National Jewish Health, one of the country’s leading respiratory centers, immunologists report that certain biologic-treated patients no longer need their rescue inhalers at all. For the millions of families touched by both chronic respiratory disease and cognitive decline, this is worth paying attention to, because the relationship between breathing, oxygen delivery, and brain health is far more intimate than most people realize.
The most striking data comes from tezepelumab, marketed as Tezspire, where up to 55 percent of patients with a specific inflammatory profile achieved clinical remission in real-world studies published in the journal Allergy in 2025. Meanwhile, the FDA approved an entirely new biologic called depemokimab in December 2025 that requires only two injections per year, a schedule that would have seemed implausible even five years ago. This article covers the latest biologics reshaping severe asthma treatment, what remission actually means in this context, the active research into whether patients can safely stop using inhalers, and why caregivers managing both respiratory and neurological conditions should be paying close attention.
Table of Contents
- How Effective Are New Asthma Biologics, and Can Patients Really Go Off Inhalers?
- Depemokimab — What a Twice-Yearly Injection Means for Patients and Caregivers
- Tezepelumab and the Science of Upstream Blockade
- Comparing Biologic Options — Which Drug Fits Which Patient?
- Risks of Stepping Down Too Fast — What Can Go Wrong
- The Asthma-Brain Connection — Why Dementia Caregivers Should Care
- What Comes Next in Asthma Biologic Research
- Conclusion
- Frequently Asked Questions
How Effective Are New Asthma Biologics, and Can Patients Really Go Off Inhalers?
The short answer is that some patients are approaching that threshold, but we are not quite there yet in terms of formal medical guidance. Biologics are currently approved as add-on therapies, meaning they are designed to work alongside inhalers, not replace them. However, the results have been dramatic enough that researchers are now actively testing whether well-controlled patients can step down from inhaled corticosteroids entirely. AstraZeneca’s ARRIVAL study, which is currently enrolling patients, is specifically designed to answer this question for tezepelumab. It is the first major trial to directly assess whether patients on a biologic can safely reduce or stop their maintenance inhaled asthma therapy. The data supporting this line of inquiry is compelling. In the NAVIGATOR and DESTINATION trials, 46 percent of patients on tezepelumab achieved complete clinical response at 52 weeks, compared to just 24 percent on placebo. Over longer follow-up periods extending beyond one and two years, 33.5 percent achieved on-treatment clinical remission, versus 26.7 percent on placebo. These are not trivial differences.
Complete clinical response means no exacerbations, normalized lung function, and controlled symptoms. Remission goes a step further, suggesting sustained disease control that persists over time. For comparison, asthma remission was not even a serious clinical concept a decade ago. The fact that a third of patients in a rigorous trial reached that benchmark has shifted how pulmonologists think about the ceiling of asthma treatment. That said, there is an important caveat. Remission in asthma does not mean the same thing as remission in cancer. It describes a state of disease control while on treatment, not necessarily a cure. When patients in omalizumab studies discontinued the biologic, only 47.7 percent remained exacerbation-free, compared to 67 percent who stayed on the drug. Going off inhalers is not the same as going off all treatment, and any step-down should happen under careful medical supervision with gradual tapering strategies, which a scoping review on biologic discontinuation found to be more successful than abrupt cessation.
Depemokimab — What a Twice-Yearly Injection Means for Patients and Caregivers
The FDA approved depemokimab, branded as Exdensur, on December 16, 2025, and it introduced something genuinely new to the biologic landscape: a dosing schedule of just once every six months. Made by GSK, it is administered as a 100 milligram subcutaneous injection, and for anyone managing the care of a person with both severe asthma and cognitive impairment, the reduction in treatment burden is significant. Most existing biologics require monthly or biweekly injections, which means regular clinic visits or self-injection routines that can be difficult for patients with memory problems to maintain independently. Two appointments a year is a fundamentally different proposition. In the Phase III SWIFT trials, depemokimab reduced asthma exacerbations by 58 percent in SWIFT-1 and 48 percent in SWIFT-2 compared to placebo over 52 weeks. A pooled analysis of both trials showed a 72 percent reduction in exacerbations that required hospitalization or emergency department visits.
That last number matters enormously for dementia caregivers, because emergency hospitalizations are among the most destabilizing events for a person with cognitive decline. The disruption to routine, the unfamiliar environment, the sedating medications, and the physical stress of an asthma crisis can accelerate confusion and functional decline in ways that persist long after the patient returns home. However, depemokimab is approved specifically for severe eosinophilic asthma, which means it targets a particular inflammatory subtype driven by elevated eosinophil counts. It will not work for every asthma patient. If eosinophil levels are low or the asthma is driven primarily by other mechanisms, this drug is unlikely to provide the same benefit. The UK’s MHRA approved it one day before the FDA, on December 15, 2025, and European approval is expected in early 2026, so international availability is expanding quickly, but appropriate patient selection remains critical.
Tezepelumab and the Science of Upstream Blockade
What makes tezepelumab different from most other asthma biologics is where it intervenes in the inflammatory cascade. Rather than targeting a single downstream molecule like interleukin-5 or immunoglobulin E, it blocks thymic stromal lymphopoietin, known as TSLP, which sits upstream of multiple inflammatory pathways. Think of it as shutting off the faucet rather than mopping the floor. This mechanism gives tezepelumab a broader reach, making it effective across both T2-high asthma, which is driven by eosinophilic inflammation, and T2-low asthma, which has historically been harder to treat with biologics. The real-world remission data from Gates and colleagues, published in 2025 in the journal Allergy, found that up to 55 percent of T2-high severe asthma patients achieved clinical remission on tezepelumab. That figure came from clinical practice rather than a controlled trial, which makes it both more encouraging and more complicated to interpret.
Real-world patients are messier than trial populations. They have comorbidities, inconsistent medication adherence, and varying definitions of what feeling better actually means. The fact that remission rates held up in that environment suggests the effect is robust. For families navigating the overlap of asthma and dementia, tezepelumab’s broad efficacy is particularly relevant. Older adults with cognitive decline often have complex inflammatory profiles that do not fit neatly into the T2-high or T2-low categories. A biologic that works across both phenotypes removes one layer of diagnostic complexity from an already complicated clinical picture. The ongoing ARRIVAL study will provide the next critical piece of evidence, specifically whether patients achieving this kind of control can begin stepping away from daily inhaled medications, which carry their own side effects, including oral thrush, hoarseness, and in some patients, mood and cognitive effects from systemic steroid absorption.
Comparing Biologic Options — Which Drug Fits Which Patient?
Choosing among asthma biologics is not a matter of picking the newest or most talked-about option. Each drug targets a different mechanism, and the right choice depends on the patient’s specific inflammatory profile, comorbidities, and practical circumstances. Omalizumab, the oldest biologic in this class, targets immunoglobulin E and works best in allergic asthma. It has the longest track record, with data showing that 67 percent of patients who continued treatment remained exacerbation-free. It is a reasonable choice for patients whose asthma is clearly allergy-driven, but it requires injections every two to four weeks and does not address non-allergic inflammation. Depemokimab’s twice-yearly dosing makes it the most convenient option for patients who struggle with frequent medical appointments, a group that includes many older adults with mobility limitations or cognitive impairment. Its 72 percent reduction in severe exacerbations requiring hospitalization is the most relevant number for caregivers worried about emergency department visits.
Tezepelumab offers the broadest mechanism and the strongest remission data but requires monthly injections. For a patient living independently with mild cognitive impairment, the monthly schedule might be manageable with a reminder system. For a patient in moderate-stage dementia, it likely requires a caregiver to coordinate each visit. Then there are the pipeline drugs that expand the picture further. Sanofi’s amlitelimab, currently in Phase 2, showed greater than 70 percent reduction in exacerbations in a biomarker-defined subgroup with both elevated eosinophils and elevated neutrophils. This mixed inflammatory profile has been notoriously difficult to treat, and if amlitelimab’s results hold up in larger trials, it could fill a gap that current biologics leave open. Itepekimab, which targets interleukin-33, is being studied not only for asthma but also for COPD in the Phase III AERIFY trials and for bronchiectasis in Phase 2, with results expected in 2026. The takeaway is that the biologic landscape is diversifying rapidly, and patients who did not respond to one drug may find success with another that targets a different pathway.
Risks of Stepping Down Too Fast — What Can Go Wrong
The enthusiasm around biologic-induced remission has to be tempered by a practical reality: stopping inhalers without careful medical oversight can be dangerous. Asthma remains a disease that kills people, and the underlying airway inflammation can persist even when symptoms are absent. A scoping review on discontinuation of biologic therapy in severe asthma found that gradual tapering strategies produce significantly higher success rates than abrupt discontinuation. Patients who suddenly stopped their maintenance medications were more likely to experience rebound exacerbations, sometimes severe ones. This warning is especially important for older adults with coexisting cognitive impairment. A person with dementia may not reliably communicate early warning signs of an asthma flare, such as increased nighttime coughing, subtle shortness of breath during activity, or a gradual increase in mucus production.
By the time symptoms become obvious to a caregiver, the exacerbation may already be advanced. The omalizumab discontinuation data makes this point clearly: even among patients who had achieved excellent control on the biologic, nearly a third who stopped treatment experienced exacerbations that those who continued did not. Stepping down from inhalers while on a biologic is a different proposition from stopping both the biologic and the inhalers, and no current guideline recommends the latter. There is also the question of insurance and access. Biologics are expensive, and coverage decisions can change. If a patient has tapered off inhalers based on biologic-maintained control and then loses access to the biologic due to a formulary change or prior authorization denial, they could find themselves without either layer of protection. Any step-down plan needs to account for this contingency, ideally by keeping a rescue inhaler prescription active and ensuring the patient or caregiver knows when to use it.
The Asthma-Brain Connection — Why Dementia Caregivers Should Care
Chronic respiratory disease and cognitive decline share more biology than most people appreciate. Poorly controlled asthma leads to intermittent hypoxia, periods where the brain receives less oxygen than it needs. Over years, this contributes to vascular damage in the brain, white matter changes, and accelerated cognitive decline.
Studies have shown that older adults with asthma have higher rates of cognitive impairment than age-matched controls, and severe exacerbations requiring hospitalization are associated with measurable drops in cognitive function that may not fully recover. By dramatically reducing exacerbations and potentially eliminating the need for systemic corticosteroid bursts, which themselves carry cognitive side effects including confusion, agitation, and psychosis, biologics may be protecting the brain while treating the lungs. For a caregiver managing a loved one with both conditions, the most important number in the depemokimab data may be that 72 percent reduction in hospitalizations. Every avoided emergency visit is a disruption that the brain does not have to endure.
What Comes Next in Asthma Biologic Research
The field is moving toward a question that would have seemed premature five years ago: can asthma be functionally cured? The ARRIVAL study’s results, expected in the coming years, will be the first rigorous answer to whether tezepelumab-treated patients can safely eliminate maintenance inhalers. If the answer is yes, even for a subset of patients, it will redefine what treatment goals look like in severe asthma. Meanwhile, the pipeline continues to expand.
Itepekimab’s Phase III COPD trials and Phase 2 bronchiectasis data, expected in 2026, could broaden the relevance of anti-inflammatory biologics beyond asthma into other chronic airway diseases that affect older adults. For families dealing with the intersection of respiratory and neurological disease, the trajectory is cautiously optimistic. The biologics already available are producing outcomes that were not achievable a decade ago, and the drugs in development target an even wider range of inflammatory mechanisms. The practical challenge now is ensuring that older adults with cognitive impairment, who stand to benefit enormously from reduced treatment burden and fewer emergency hospitalizations, actually gain access to these therapies through informed clinical teams and supportive coverage policies.
Conclusion
The era of asthma biologics has moved from controlling symptoms to pursuing remission, and the implications reach well beyond the lungs. Depemokimab’s twice-yearly dosing and 72 percent reduction in severe exacerbations, tezepelumab’s remission rates approaching 55 percent in real-world practice, and the ongoing ARRIVAL study testing whether inhalers can be safely discontinued represent a genuine shift in what is possible for people with severe asthma. For caregivers managing loved ones with both respiratory disease and cognitive decline, these advances offer something concrete: fewer hospitalizations, fewer corticosteroid bursts, and less treatment complexity. None of this means inhalers should be abandoned without medical guidance.
The data on biologic discontinuation makes clear that tapering must be gradual and monitored, and the underlying disease does not simply disappear because symptoms have resolved. But the direction is unmistakable. The conversation between patients, caregivers, and pulmonologists is no longer just about managing asthma. It is increasingly about whether, for some patients, the disease can be put into a state of sustained remission that changes daily life in meaningful ways.
Frequently Asked Questions
Are asthma biologics a cure for asthma?
No. Biologics can produce clinical remission, meaning sustained symptom control and normalized lung function while on treatment. However, this is not the same as a cure. The underlying disease process may still be present, and discontinuing treatment can lead to return of symptoms. Research is ongoing to determine how long remission lasts and whether some patients can eventually stop treatment altogether.
Can I stop using my inhaler if I start a biologic?
Not without your doctor’s explicit guidance. Biologics are currently approved as add-on therapies to existing asthma medications. The ARRIVAL study is actively investigating whether patients on tezepelumab can safely reduce or stop inhaled therapies, but until those results are available, inhalers should not be discontinued independently.
Which asthma biologic requires the fewest injections?
Depemokimab, approved in December 2025, requires only two injections per year, administered every six months. This is the least frequent dosing schedule among all approved asthma biologics. Most others require monthly or biweekly injections.
Do asthma biologics work for all types of asthma?
No. Most biologics target specific inflammatory pathways and work best in patients with matching biomarker profiles. Depemokimab targets eosinophilic asthma specifically. Tezepelumab has the broadest mechanism, working across both T2-high and T2-low asthma by blocking the upstream cytokine TSLP. Your doctor will use blood tests and other markers to determine which biologic, if any, is appropriate.
Is there a connection between asthma and dementia risk?
Research suggests that poorly controlled asthma, particularly when it causes repeated episodes of low oxygen or requires frequent systemic corticosteroid use, may contribute to accelerated cognitive decline. Severe exacerbations requiring hospitalization have been associated with measurable drops in cognitive function. By reducing exacerbations, biologics may offer indirect neuroprotective benefits, though this has not been the primary focus of clinical trials.
